PD-1 and PD-1 ligands: From discovery to clinical application

1.1kCitations
Citations of this article
998Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Programmed cell death-1 (PD-1, Pdcd1), an immunoreceptor belonging to the CD28/CTLA-4 family negatively regulates antigen receptor signaling by recruiting protein tyrosine phosphatase, SHP-2 upon interacting with either of two ligands, PD-L1 or PD-L2. Because of the wide range of ligand distribution in the body, its biological significance pervades almost every aspect of immune responses including autoimmunity, tumor immunity, infectious immunity, transplantation immunity, allergy and immunological privilege. In this review, we would like to summarize the history of PD-1 research since its discovery and recent findings that suggest promising future for the clinical application of PD-1 agonists and antagonists to various human diseases. © The Japanese Society for Immunology. 2007. All rights reserved.

Cite

CITATION STYLE

APA

Okazaki, T., & Honjo, T. (2007, July). PD-1 and PD-1 ligands: From discovery to clinical application. International Immunology. https://doi.org/10.1093/intimm/dxm057

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free